Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cor Therapeutics Inc. (CORR) -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (453)	5/13/1999 8:20:00 AM
From: SemiBull	Respond to of 712

J&J-Centocor Talks Reportedly Off By The Associated Press NEW YORK (AP) -- Merger talks between Johnson & Johnson and Centocor Inc. have been called off for the time being, according to a source close to the negotiations. The New Brunswick, N.J., health care and pharmaceutical giant had been in talks to acquire biotechnology firm Centocor, which could have given Johnson & Johnson a much needed presence in the cardiovascular drug market. It wasn't immediately clear what led to the stoppage of talks, but here is the possibility they may resume, the source said Wednesday. Officials at Johnson & Johnson and Centocor couldn't be reached immediately for comment. Centocor makes ReoPro, a popular drug used to prevent blood clotting that had sales of $365 million last year. However, Centocor's existing agreement with Eli Lilly & Co. to co-market ReoPro may have proven to be a stumbling block -- Eli Lilly and Johnson & Johnson are competitors in a number of arenas. Analysts had said that Johnson & Johnson might want to acquire the drug maker to help revive weakening sales of its cardiovascular stents, the tiny devices that hold arteries open. In addition to drugs, Johnson & Johnson also makes many consumer products such as Band-Aids, Tylenol and baby shampoo.

To: LLCF who wrote (453)	5/13/1999 11:19:00 AM
From: Edscharp	Respond to of 712

"I'm hoping for CHIR to take them out for stock" Dave, I hope no one buys Cor. I don't hate Chiron. In a buyout scenario I'd probably keep half of my Chiron shares. I just don't think Chiron as a company is nearly as exciting as Cor alone. Ed